Blood coagulation or fibrinolysis factors (A61K38/36)

Hemostatic sponge and method of its production // 2628809
FIELD: pharmacology.SUBSTANCE: group of inventions is a hemostatic sponge containing a freeze-dried substrate and active substance, characterized in that it contains sodium alginate as the base, and as an active ingredient fibrin monomer with the following ratio of the components in the final aqueous solution in the volume per 1 litre in wt %: Sodium alginate - 0.1-8.0, Fibrin-monomer - 0.01-0.5, as well as a method for obtaining a hemostatic sponge.EFFECT: expansion of the assortment of hemostatic sponges and can be used to stop bleeding in surgical practice, in combat situations, in the aftermath of mass catastrophes and terrorist acts, and in combat situations.4 cl, 13 ex
Treatment of coagulation disease by administration of recombinant vwf // 2628537
FIELD: medicine.SUBSTANCE: group of inventions relates to a method of treating von Willebrand's disease or hemophilia A in a patient in need of treatment comprising administering to the patient a recombinant vWF (vWF) factor so that the half-life of factor VIII is prolonged compared to a patient administered vWF derived from blood plasma, where pFB is not modified with an aqueous soluble polymer. In this case, the pFB is a composition of high molecular weight PV multimers containing at least 20% of the PV emperors or higher-order multimers, with the rVB having a higher specific activity than the vWF derived from the blood plasma. The group of inventions also relates to a method for treating hemophilia A or vWF in a patient in need of treatment that includes administering to the patient a recombinant vWF (vWF) factor, wherein the half-life of FVIII is at least 1.5 times higher than the half-life of FVIII in the patient being treated Von Willebrand factor derived from blood plasma.EFFECT: increase in the half-life of FVIII in the treatment of von Willebrand disease or haemophilia A in the subject.29 cl, 5 ex, 22 dwg, 34 tbl

Derivatives of blood coagulation factors vii and viia, conjugates and complexes containing them and their application // 2620072
FIELD: biotechnology.SUBSTANCE: invention relates to production of blood coagulation derivatives VII and VIIa, their conjugates with polymers capable of increasing the half-life of blood from the bloodstream, complexes containing them obtained by carrier binding to the conjugate, to genes encoding the derivatives, to expression vectors containing these genes, transformants with introduced expression vectors, to methods for their preparation, pharmaceutical compositions and treatment methods, and can be used in medicine to prevent or treat hemophilia or to improve blood coagulation. A FVII derivative is obtained which is linked at its C-terminus to the peptide linker for binding to a non-peptidyl polymer capable of increasing the half-life of FVII or FVIIa from the blood stream. At that, the peptide linker is a partial sequence of superoxide dismutase SOD1, its mutated sequence or GGGGSC sequence.EFFECT: invention allows to obtain an FVII derivative capable of binding to a carrier increasing the half-life from the blood stream while maintaining FVII activity.42 cl, 8 dwg, 3 tbl, 8 ex
Factor ii and fibrinogen for treatment of haemostatic disorders // 2606155
FIELD: medicine.SUBSTANCE: present group of inventions relates to medicine, namely to haematology and can be used for normalising impaired haemostasis. Methods include administering a clotting factor treatment consisting of FII, PCC and a three factor combination of FII, FX and FVIIa or fibrinogen and FII.EFFECT: use of these inventions enables to reduce the risk of thromboembolic complications.24 cl, 12 dwg, 2 ex

ethod of producing fibrinogen using strong anion exchange resin and fibrinogen-containing product // 2603103
FIELD: biotechnology.SUBSTANCE: group of inventions relates to biotechnology. Invention discloses a method of purifying fibrinogen, a fibrinogen-containing product and use of an anion-exchange resin, containing a hydroxylated methacrylic polymer with trimethylamino groups grafted through binding group, for producing said product using said method. Fibrinogen-containing source undergoes chromatography on anion-exchange resin based on hydroxylated methacrylate polymer with trimethylamino groups grafted through binding group. Fibrinogen-containing product is obtained, having high degree of purity without content of viruses and prions with content of fibronectin of 0.01-1.00 mcg/mg of fibrinogen, fibrinopeptide A 0.01-9.0 ng/mg of fibrinogen, with activity vWF: Ag less than 0.1 IU/mg of fibrinogen, with activity of factor XIII 0.07-1.0 IU/mg of fibrinogen and thrombin activity less than 0.007 IU/mg of fibrinogen.EFFECT: invention discloses a method of purifying fibrinogen, a fibrinogen-containing product and use of an anion-exchange resin, containing a hydroxylated methacrylic polymer with trimethylamino groups grafted through binding group, for producing said product using said method.18 cl, 5 tbl
ethod for preparing fibrin paste // 2602301
FIELD: pharmaceutics.SUBSTANCE: invention refers to pharmaceutical industry and medicine and represents a method for preparing fibrin paste, involving dissolution of fibrin in 4-6 % ammonia solution, characterised by that the fibrin powder. previously sterilized at t=120° and atmospheric pressure in 2.5 ATM, dissolved directly prior to application to the damaged section.EFFECT: invention provides preparing the sterile preparation of long storage, which can be used in different degrees of skin lesions.1 cl

Phospholipid-enriched vesicles bearing tissue factor having haemostatic activity and use thereof // 2595406
FIELD: biotechnology.SUBSTANCE: present invention relates to a method of improving procoagulant properties of tissue factor (TF) expressed in eukaryotic cells, and can be used in medicine. Modified tissue factor bearing microvesicle produced in accordance with present invention can be used as procoagulant agent for treating bleeding, wound healing and stimulating angiogenesis in tissues.EFFECT: invention improves procoagulant properties of tissue factor due to that obtained TF bearing microvesicle is generated from lipid membranes or their fragments of eukaryotic cells, in which tissue factor is expressed, as well as additional additive of negatively charged phospholipid.18 cl, 16 dwg, 2 tbl, 5 ex

ethod and apparatus for producing serum with thrombin from one donor // 2589648
FIELD: medicine.SUBSTANCE: group of inventions relates to transfusion medicine. Serums with thrombin are produced. For this purpose liquid blood sample is obtained, having first aliquot of liquid blood with procoagulant to make prothrombinaze enzyme complex associated with surface of procoagulant agent, which enables to obtain activated procoagulant agent, which can be stored. Activated procoagulant agent then may be subjected to interaction with second liquid blood aliquot containing prothrombin to obtain serum with Thrombin, which can be extracted and subjected to interaction with fibrinogen for preparing fibrin. To obtain serum with Thrombin special device is used containing reaction chamber with one or several compartments to hold procoagulant agent and liquid part of blood without flow. Procoagulant agent can reaction with said liquid part of blood to form fibrin gel, appliances to feed fluid into and from reaction chamber, means to retain solid particles in reaction chamber; agent for serum separation with Thrombin from fibrin gel. Further, device also comprises ventilation hole made with possibility of avoiding long period of staying under excessive pressure of reaction chamber. At that, one or several solid floating objects are present in reaction chamber, wherein solid loose objects, have diameter within range of 50 mcm and 2 mm, and other solid loose objects are characterised by dimensions selected for grinding of fibrin gel, and in cross section have, at least 4 mm.EFFECT: group of inventions allows eliminating risk of toxic reaction in patient in response to introduction of serum with Thrombin, risk of immunogenic reactions and risk of infectious diseases transmission from donors.25 cl, 8 dwg, 2 tbl

edicament for therapeutic treatment and/or improvement of sepsis // 2580756
FIELD: medicine.SUBSTANCE: group of inventions relates to medicine and concerns a medicament for therapeutic treatment and/or ameliorating sepsis, which comprises thrombomodulin as an active ingredient. Medicament is to administer to a patient with severe sepsis accompanied with one or more organ dysfunctions, with one or more organ dysfunctions selected from the group consisting of liver dysfunction, kidney dysfunction, respiratory organ dysfunction, and circulatory organ dysfunction wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4. Also proposed medicament for reducing mortality in patients with sepsis.EFFECT: group invention provides a reduction of mortality in patients with sepsis, namely in patients with severe sepsis, accompanied by one or more liver dysfunction, kidney, respiratory organs or circulation organs.30 cl, 4 tbl, 8 ex

Preparations containing von willebrand factor (vwf) and methods, kits and applications related to them // 2579977
FIELD: biotechnology.SUBSTANCE: shortened vWF variants are produced, connected with the Fc-part of immunoglobulin, capable to bind FVIII.EFFECT: invention enables to facilitate the production and purification of FVIII, contributes to prolongation of the half-life of FVIII in blood.12 cl, 11 dwg, 1 tbl, 3 ex

Treating peripheral vascular diseases by means of umbilical cord tissue cells // 2576836
FIELD: medicine.SUBSTANCE: pharmaceutical composition containing fibrin glue and a recovered homogenous cell population produced from human umbilical cord tissues in an amount effective to treat a disease; the umbilical cord tissue is substantially blood-free, is applied locally. The above recovered homogenous cell population is self-renewing and propagating in a culture, has a differentiation potential and does not express CD117 and/or telomerase.EFFECT: using the given inventions enables increasing reperfusion in a patient suffering a peripheral vascular disease by the local use of umbilical cord tissue cells.34 cl, 7 ex, 13 dwg, 7 tbl
Reinforced resorbable synthetic matrix for haemostatic applications // 2574016
FIELD: chemistry.SUBSTANCE: group of inventions relates to a reinforced resorbable blood clotting agent containing at least one haemostatic agent in one layer of nonwoven synthetic material consisting of a mixture of pressed fibre staples of a polyglycolide and polylactide copolymer and a polydioxanone in weight ratio of 80:20 to 60:40, with density of 50 to 200 mg/cm3.EFFECT: agent does not lead to the formation of an acidic environment not conducive cell survival.19 cl, 3 tbl, 5 ex

odified factor vii-based polypeptides and thereof application // 2571931
FIELD: chemistry.SUBSTANCE: invention relates to field of biotechnology, namely to obtaining modified factor FVII, and can be used in medicine. Polypeptide FVII is modified by substitution of amino acid residue, selected from D196L, D196I, D196Y, K197E, K197D, K197L, K197M, K197I, K197V, K197F, K197W, K197Y, K199D and K199E, in amino acid sequence FVII, represented as SEQ ID NO: 3, or in respective residues of its precursor with SEQ ID NO: 1 or SEQ ID NO: 2. Polypeptide can contain additional modifications of amino acids, which improve its functional properties.EFFECT: invention makes it possible to obtain modified polypeptide FVII, which, when activated, possesses increased coagulant activity and/or increased resistance to inhibitors in comparison with non-modified polypeptide FVII with sequence, given in SEQ ID NO: 3.48 cl, 7 dwg, 23 tbl, 17 ex

ethod for producing ex vivo soluble fibrinogen // 2571288
FIELD: medicine.SUBSTANCE: fresh-frozen plasma is unfrozen and centrifuged; the produced cryoprecipitate is solubilised and treated with aluminium hydroxide; the produced suspension is centrifuged; the produced deposit containing non-target proteins are rejected; the supernatant is treated with polyethylene glycol; the suspension is centrifuged; the supernatant is rejected; the deposit is solubilised and subject to viral inactivation, cleaned from viral inactivation products by shaking with Vaseline oil and re-precipitating with glycerol; the deposit procedure is repeated twice; the produced fibrinogen solution is bottled and lyophilised.EFFECT: producing fibrinogen, which possesses fast solubility.2 ex, 2 dwg, 3 tbl

Von willebrand factor or factor viii and von willebrand factor for treatment of coagulopathy, induced by platelet inhibitors // 2563236
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to the field of pharmaceutics and medicine and deals with the application of the von Willebrand factor in a combination with factor VIII for the treatment and/or prevention of a haemorrhage episode, associated with thrombopathy, induced with platelet-inhibiting substances, the where platelet-inhibiting substance is represented by an inhibitor of ADP receptor or a combination of the inhibitor of FDP receptor and cyclooxygenase inhibitor. The invention also relates to a composition and a method of treatment and/or prevention of a disorder, associated with the haemorrhage, associated with thrombopathy, induced by the platelet-inhibiting substances.EFFECT: group of inventions provides the reduction or prevention of undesirable instances of the haemorrhage after the introduction of anticoagulants or fibrinolytics.19 cl, 6 dwg, 5 tbl, 2 ex

Factor vii chimeric molecules // 2563231
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions relates to medicine, namely to haematology and can be applied in treatment of disorders, associated with haemorrhage. Method in accordance with invention includes introduction of factor VIIa chimeric polypeptide to subject, where said factor VIIa chimeric polypeptide includes domain EGF-2 and factor VII catalytic domain; GLA domain, selected from the group, consisting of factor VII GLA domain, factor IX GLA domain and protein S GLA domain; and EGF-1 domain, selected from the group, consisting of factor IX EGF-1 domain and protein S EGF-1 domain. Factor VIIa chimeric polypeptide in accordance with invention includes EGF-2 domain and factor VII catalytic domain; protein S GLA domain; and EGF-1 domain, selected from the group, consisting of protein S EGF-1 domain and factor IX EGF-1 domain. Molecule of nucleic acid by invention codes factor VIIa chimeric polypeptide. Inventions also deal with vector, including molecule of nucleic acid, cell, including factor VIIa chimeric polypeptide and cell, including vector.EFFECT: application of inventions makes it possible to reduce doses of introduced protein and attenuate undesirable side effects.11 cl, 7 dwg, 5 ex

ethod of providing improved sealing by means of fibrin // 2556960
FIELD: medicine.SUBSTANCE: invention relates to medicine. Described are: fibrin matrix, method of its obtaining and method of processing or prevention of defect on wet tissue of object requiring processing. Described is application for hermetic sealing of defect in mucous membrane or other wet tissue.EFFECT: fibrin matrix is efficient for sealing tissue leakages.35 cl, 3 dwg, 1 tbl, 3 ex
ethod of treating acute haemorrhoid // 2553313
FIELD: medicine.SUBSTANCE: trombolytic is administered intranodularly into a thrombosed haemorrhoid. After the haemorrhoidal contents gets soft, it is punctured with removing lysed blood, and an anti-inflammatory glucocorticosteroid is administered into the haemorrhoid cavity, which is followed by a tight external perianal tamponade.EFFECT: method enables providing the clinical effectiveness of acute haemorrhoid.3 cl, 1 ex

ethod of preventing bleeding caused by use of streptokinase in experiment // 2552339
FIELD: veterinary medicine.SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injection is added to the lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin monomer at a concentration of 11 mg/ml and urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. At that the dose of fibrin-monomer is 0.25 mg/kg.EFFECT: method is highly effective the prevention of bleeding caused by the use of streptokinase, prior to surgical interferences.1 ex, 2 dwg

ethod of prevention of bleeding caused by use of dabigatran etexilate in experiment // 2552331
FIELD: veterinary medicine.SUBSTANCE: solution is administered intravenously to chinchilla male rabbits one hour prior to surgical interference. The solution is prepared as follows: sterile distilled water for injections is added to lyophilised fibrin-monomer with urea, so that the resulting solution contains fibrin-monomer at a concentration of 11 mg/ml and the urea at a concentration of 150 mg/ml, and stirred until complete dissolution of the substance. The dose of fibrin-monomer is 0.25 mg/kg.EFFECT: method is highly effective for prevention of bleeding caused by the use of dabigatran etexilate in the experiment.2 dwg, 1 ex

ethod for preventing intraoperative bleeding caused by preoperative introduction of heparine // 2544805
FIELD: medicine.SUBSTANCE: solution containing fibrin monomer in the concentration of 11 mg/ml and urea in the concentration of 150 mg/ml is introduced intravenously into male rabbits experimentally one hour before the surgical intervention. A dose of fibrin monomer is 0.25 mg/kg.EFFECT: method possess the high effectiveness as both reduces the bleeding volume, but causes the severe haemodynamic disturbances and allergic reactions.2 dwg

ethods, compositions and sets for lyophilisation // 2540480
FIELD: chemistry.SUBSTANCE: invention relates to a method of lyophilisation of a composition, which contains purified antithrombin III (AT III) and a crystallised substance, selected from alanine, mannitol, glycine or NaCl. The claimed method includes freezing the composition at a temperature from -52°C to -60°C for 6-15 hours, annealing the composition at -30°C for 1 hour, re-freezing the composition at a temperature from -52°C to -60°C for 2-15 hours at keeping the product temperature between -48°C and -52.7°C for 4-10 before lyophilisation and drying the composition with obtaining a lyophilised cake. The invention also relates to a pharmaceutical set, which contains the said lyophilised cake and a liquid reagent.EFFECT: invention provides obtaining the lyophilised composition, containing AT III, which preserves its activity and stability.14 cl, 24 dwg, 5 tbl, 2 ex

odified von willebrand factor with prolonged half-cycle in vivo, using it and methods for preparing // 2528855
FIELD: medicine.SUBSTANCE: invention refers to biotechnology, more specifically to modified von Willebrand factor (VWF), and can be used in medicine. A recombinant method is used to preparing modified VWF fused in C-terminal of its primary translation product with N-terminal of albumin by the linker SSGGSGGSGGSGGSGGSGGSGGSGGSGGSGS. The prepared modified VWF is used as a part of the pharmaceutical composition for treating or preventing coagulation failure.EFFECT: invention enables preparing the modified VWF which maintains its ability to N-terminal dimerisation and C-terminal multimerisation with a prolonged half-period of functional blood plasma occurrence as compared to the half-period of functional VWF occurrence.17 cl, 5 dwg, 4 tbl, 11 ex
ethod of correcting haemostatic disorders in case of chronic calculous cholecystitis at background of chronic hepatitis or cirrhosis of liver // 2526117
FIELD: medicine.SUBSTANCE: to correct haemostatic disorders in case of chronic calculous cholecystitis at the background of chronic hepatitis or cirrhosis of liver, preoperative correction of haemostasis with the preparation prothromplex 600, introduced intravenously at a rate not higher than 2 ml/min in a dose of 20 IU/kg of the patient's body weight, is carried out 3 days before endosurgical treatment. After that, on the first day after operation 20 IU/kg of prothromplex 600 and additionally 10 mg/kg of etamsylate and 25 mg/kg of aminomethyl are introduced intravenously. The preparations are introduced 1 time per day for 3 days with obligatory control of haemostasis indices.EFFECT: method makes it possible to enhance the clinical effect due to an improvement of haemostasis system indices, connected with an increase of quantitative indices of a coagulation link, at the background of normalisation of the aggregation activity of platelets, as well as an arrest of hypocoagulation due to normalisation of the prothrombin complex, which makes it possible to twice reduce the treatment duration.2 tbl, 1 ex
Purification and application of factor, contributing to wound healing // 2520817
FIELD: chemistry.SUBSTANCE: group of inventions relates to the field of biotechnology. Claimed is a method of purification of a factor, contributing to wound healing, which represents a hepatocyte growth factor (HGF). All stages of purification are carried out in the presence of antithrombin III (AT-III). In accordance with the claimed method carried out are: defrosting of the frozen HGF-containing source and removal of sediment from the defrosted source. After that, the obtained solution, which contains a supernatant and AT-III, is brought in contact with a carrier for affinity chromatography on an immobilised heparin. Then, the solution is separated from the carrier for affinity chromatography. The carrier is brought in contact with a desorption buffer with ionic strength sufficient for HGF desorption. The desorption buffer, containing HGF, AT-III and histidine-rich glycoprotein (HRGP) is collected. Also claimed are wound-healing compositions, which contain HGF, AT-III and/or HRGP, purified by the claimed method.EFFECT: inventions make it possible to increase step-by-step output of the hepatocyte growth factor, with the hepatocyte growth factor being concentrated in eluate in the presence of AT-III.26 cl, 2 tbl, 6 ex

Biogel // 2503464
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics. There are developed agent for forming a biogel, biogels for hemostasis, wound closure, tissue engineering and targeted drug delivery. The agent contains a soluble carrier whereon a number of fibrinogen-binding groups is immobilised. The biogel that contains fibrinogen molecules and a number of soluble carriers applicable for intravenous and/or local administration; each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier, and each fibrinogen molecule is bound to at least two fibrinogen-binding groups so that the fibrinogen molecules occurs to be bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen molecules. The biogel containing fibrin monomers and a number of soluble carriers applicable for intravenous and/or local administration, wherein each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier, while the fibrin monomers are bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen monomers. The biogel containing fibrin and a number of soluble carriers applicable for intravenous and/or local administration, wherein each carrier comprises a number of fibrinogen-binding groups immobilised on the carrier with the fibrin monomers in fibrin are covalently bound to each other by peptide bonds, and the fibrin monomers in fibrin are bound to each other through the carriers by non-covalent bonds between the fibrinogen-binding groups and the fibrinogen monomers. A method for forming the biogel involving a contact of the fibrinogen molecules with a number of soluble carriers. A method for hemostasis by topical administration of the biogel at a haemorrhage or a wound. Using a number of soluble carriers applicable for intravenous and/or local administration. A pharmaceutical formulation for topical administration containing the biogel, agent or a number of soluble carriers.EFFECT: using the declared invention enables preparing the agents requiring no toxic reagents to be used, have a minimal risk of allergic reactions, and are easy to prepare and use.2 tbl, 4 dwg, 5 ex
ethod for early deep burn healing // 2499603
FIELD: medicine.SUBSTANCE: invention relates to medicine and may be used for early deep burn healing. That is ensured by taking a patient's healthy tissue transplant. A cell suspension is prepared in the laboratory environment and applied together with fibrin glue (Tissucol). The intraoperative use of the invention enables reducing the length of staying on the operative table. Besides, the cell suspension applied together with fibrin glue is presented by the integral cell elements that promotes the better adhesion and the functional state continuance.EFFECT: invention enables fixing the cell suspension reliably on the burn wound surface with using no minor chemical elements and additives when processing the cell material.1 ex
ethod for homeostatic disorder correction in children with hepatic hemangiomas // 2483737
FIELD: medicine.SUBSTANCE: invention relates to medicine, particularly to paediatrics, X-ray surgery, paediatric surgery, and concerns the hemostatic disorder correction in the children with hepatic hemangiomas. For this purpose, three days before the endovascular embolisation of the hepatic hemangioma, Protromplex 600 - a preparation of plasma factors II, VII, IX, X is administered intravenously in a dose of 20 IU/kg at max. 2 ml/min; on the first postoperative day, Protromplex is administered in the same dose, and further Fraxiparine is administered subcutaneously in a dose of 158 IU/kg of body weight for 3 days.EFFECT: presented dose schedule of the preparations provides the effective and safe correction of hemostatic disorders in the children with hepatic hemangiomas due to normalising the internal and external mechanisms of blood coagulation and fibrinolysis.1 ex

ethod of treating acute venous thromboses of various localisations with underlying hemorrhagic complications // 2477636
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely coagulology, and may be used in treating acute venous thrombosis of various localisations in the clinical conditions accompanied by existing or else threatening hemorrhagic complications. For this purpose, with underlying intake of low-molecular heparins (LMHs) in preventive doses, human Antithrombin III 1000 IU is additionally introduced every three days; total course dose is 5000-10000 IU.EFFECT: method provides higher clinical effectiveness ensured by intensified antithrombotic potential of LMH with causing no hemorrhagic syndrome aggravations in the patients having both low, and normal endogenic antithrombin III level.1 tbl, 3 ex

Compositions of biocompatible microparticles of alginic acid for regulated release of active ingredients in intravenous introduction // 2476235
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to medicine, particularly to the compositions of biocompatible microparticles of alginic acid for regulated release of the active ingredients in intravenous introduction, to a method for preparing and using it. The composition contains microparticles of alginic acid of 5 mcm or less with negative Z-potential; the active ingredient represents blood coagulation factor.EFFECT: group of inventions provides a combination of size adequate for prolongation of blood half-life or survival of the active ingredient, with lower hepatic absorption and fast cell clearance in intravenous introduction.23 cl, 5 ex, 8 tbl, 3 dwg

Expression plasmid dna pcid-proc coding human protein c and cell line dg-cid-proc-1 producing recombinant human protein c // 2469093
FIELD: medicine.SUBSTANCE: invention refers to biotechnology, namely plasmid DNA pCID-PROC for expression of recombinant human protein C, cell lines of Chinese hamster ovary DG-CID-PROC-1 and a method for producing recombinant human protein C. The presented invention may be used for producing recombinant human protein C. Plasmid DNA pCID-PROC for expression of recombinant human protein C contains a sequence of full-length complementary DNA of a human protein C gene presented in List of Sequences as the sequence SEQ ID NO: 1. Plasmid DNA pCID-PROC is characterised by a physical map presented on dwg. 1. A cell line of Chinese hamster ovary DG-CID-PROC-1 is produced by transformation of the cell line of Chinese hamster ovary DG-44 by said expression plasmid DNA pCID-PROC. The method for producing recombinant human protein C involves culture of said cell line DG-CID-PROC-1 in a nutrient medium and recovery of produced target protein from a culture fluid.EFFECT: invention provides higher production performance of the protein C expression system and simplified recovery, activation and purification of recombinant activated human protein C.3 cl, 3 dwg, 2 ex

ethod of sealing interintestinal anastomosis // 2464942
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to surgery, and can be applied for sealing interintestinal anastomosis. For this purpose before immersion into abdominal cavity and suturing middle wound, application of 30-40 g of dry lyophilised cryoprecipitate is performed on serous cover of small intestine on entire circumference of interintestinal anastomosis. After that, either 2-3 ml of 5% calcium chloride solution or 4-5 ml of sterile thrombin 15 U NIH/ml, dissolved in 5% solution of aminocaproic acid, are added drop by drop into said cryoprecipitate. 60 seconds after formation of gel-like fibrin film re-application of the first or the second two-component composition is carried out.EFFECT: method ensures increase of strength and biological impermeability of intestinal sutures at the background of extensive peritonitis due to efficient fixation of fibrin, which does not produce damaging impact on tissues, is capable of quick formation of fibrin film, is homologous and safe, penetrates zone of suture, filling holes from needle punctures, making it possible to close anastomosis on circumference evenly.4 dwg, 4 ex

ethod of micronisation // 2443413
FIELD: process engineering.SUBSTANCE: invention relates to micronisation of dispersion of particles containing protein with preset level of biological activity. Proposed method comprises adding protein dispersion in mincer with cyclone chamber to be minced therein under conditions including one or more parameters selected from: input pressure of 1 to 7 bar; injector pressure of 0.2 to 5 bar; loading rate of 0.1 to 5 kg/h, and gas flow rate of 30 to 100 m3/h. Mincing results in protein powder that preserves over 80% of preset level of biological activity and features distribution of particle sizes of 5 to 100 mcm, and/or 30- to 400-fold decrease in initial dispersion particle size.EFFECT: invariable and controlled distribution of particle sizes.14 cl, 8 tbl, 6 dwg

Saline solution for drug reduction or dilution // 2432157
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to methods for preparing pharmaceutical compounds for injections. To prevent agglutination, the prepared pharmaceutical compound shall have sufficient ionic strength. To prevent haemolysis or cell compression, the prepared injection pharmaceutical compound shall be roughly isotonic in relation to plasma. The method involves application of saline solutions of the concentration approximately 25 mM to 150 mM for transfer lyophilizates into the solution (or the other pharmaceutical compounds which are not liquids) or for solution dilutions on the basis of pharmaceutical compounds.EFFECT: prepared compounds if introduced do not cause hemagglutination, haemolysis or cell compression.26 cl, 4 ex, 9 tbl, 2 dwg

ethod of purification of human recombinant growth factor viia // 2429008
FIELD: medicine.SUBSTANCE: method of purification of human factor VIIa includes creation of affine sorbent, which includes immobilisation of antibodies to factor VIIa on insoluble matrix, sorption of factor VIIa on affine sorbent, further evolution of factor VII a and control of correctedness of its post-translation modification and conformation. Obtaining affine sorbent is achieved by optimal combination of NHS-activated Sepharose 4FF as hard base and combination of monoclonal antibodies, produced by clones 4F4 and 6B8 of cultivated hybridioma, selected by the highest degree of output of monoclonal antibodies to epitopes of calcium-binding domain in composition of factor VIIa. Control of correctness of post-translation modification and conformation of factor VIIa is performed by immunoassay with application of boards covered with monoclonal antibodies, produced by clone 5D9. 95%-binding of affine sorbent with factor VII a is achieved after 5 minutes of contact with one cycle of interaction with sorbent.EFFECT: reduction of factor VII purification time and expenditures on said process.4 ex, 4 dwg, 7 tbl

odified vitamin k dependent polypeptides // 2396347
FIELD: chemistry; biochemistry.SUBSTANCE: invention pertains to biotechnology. The invention describes a method of producing a modified vitamin K dependent polypeptide which involves modification of activation peptide which includes at least part of an amino acid sequence of another vitamin K dependent polypeptide and where the said part is at least 3 adjacent amino acids of activation peptide FVII, or 5 adjacent amino acids of activation peptide FX, or 5 adjacent amino acids of activation peptide FIX provided that QSFNDFTR peptide is excluded, or 8 adjacent amino acids of activation prothrombin peptide, or an extension on adjacent amino acids of the activation peptide of the second vitamin K dependent polypeptide which has length at least equal to 15% of the total length of the amino acid sequence of the activation peptide of the second vitamin K dependent polypeptide, in which the second vitamin K dependent polypeptide is selected from a group consisting of protein Z, GAS6 and protein S, and where the second vitamin K dependent polypeptide has longer half-life in plasma. The invention discloses a modified vitamin K dependent polypeptide obtained using the described method and having coagulation activity.EFFECT: invention enables production of modified vitamin K dependent polypeptides with longer half-life in plasma.40 cl, 2 dwg, 4 tbl, 7 ex
ethods of treating tracheal, bronchial or alveolar haemorrhage or hemoptysis // 2396086
FIELD: medicine.SUBSTANCE: invention refers to medicine and concerns methods of treating tracheal, bronchial or alveolar haemorrhage or haemoptysis. Substance of the invention involves intratracheal, intrabronchial or intraalveolar introduction to a person of a blood-coagulation factor which is activated factor VII.EFFECT: advantage of the invention consists in application of the blood-coagulation factor active at the earlier stages of the coagulation cascade.16 cl, 1 ex

Liquid water pharmaceutical composition containing factor vii polypeptide // 2388460
FIELD: medicine.SUBSTANCE: invention relates to medicine and concerns liquid water pharmaceutical compositions containing factor VII polypeptides and a stabilising agent, a method for producing and applying such compositions as well as a container for such a composition and application of such composition for treatment of factor VII dependent syndrome.EFFECT: invention ensures production of liquid water pharmaceutical composition containing factor VII polypeptide with decreased formation of chemical and/or physical degradation products, such as products of fermentative degradation or autocatalysis.24 cl, 8 ex, 10 tbl

ethod of transdemal drug introduction in psoriasis treatment with using electret applicators // 2386456
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to dermatology and can be used for treatment of localised psoriasis. That is ensured by applying an electret polymer film on a lesion; between an active surface thereof and an affected skin surface there is an absorbent pad impregnated with a dosage form solution. An electric charge of an applicator is specified to be similar to that of active components of the dosage form. Between the active surface of the applicator and the absorbent pad, there is a protective fluoroplastic film eliminating the fast discharge of the applicator.EFFECT: method allows intensifying diffusion of the dosage form, improving microcirculation, reducing blood viscosity, normalising skin electrical conductivity in the lesion that ensures resolution of "duty" plaques torpid to routine methods of therapy, and also ensuring pharmacoeconomic benefit.2 ex, 1 dwg, 3 cl
Textile material for haemostasis and method for making thereof // 2380117
FIELD: medicine.SUBSTANCE: invention refers to chemical-pharmaceutical industry. The material for haemostasis contains dialdehyde cellulose of the oxidation level 6.5±0.33% - 1 g, gelatinol 60±3 mg - (0.75 ml), ε-aminocapronic acid 50±0.25 mg, lysozyme 5±0.25 mg, water 5.75 ml. The method for making the textile material expressing haemostatic action consists that ε-aminocapronic acid, gelatinol and lysozyme are successively dissolved in the distilled water at room temperature. After said components are dissolved completely, the prepared solution is placed into dialdehyde cellulose solution of the oxidation level 6.5%±0.33% in the form of a cloth and kept for 2 hours. Then the cloth is wrung out, air-dried to residual humidity no more than 10% with cutting out napkins of weight approximately 1 g and dimensions 7.5×5.0 cm, then sealed in polyethylene bags and sterilised by gamma irradiation in a dose 25 kGy. Besides for haemostasis of irregularly shaped deep stab, missile and shell fragment wounds, the prepared material is ground in a rotor impact mill to lint condition (cotton wool).EFFECT: making the effective styptic (haemostatic) product of partially oxidised cellulose.1 tbl, 5 ex, 3 cl

Stabilised composition, containing factor vii polypeptide // 2373953
FIELD: chemistry.SUBSTANCE: invention relates to chemically and physically stable compositions and sets, which contain factor VII polypeptide or a factor VII related polypeptide, which can be stored, handled and used at room temperature. A set is proposed, which contains a pharmaceutical drug which contains: a) a composition which contains factor VII polypeptide and a combination of sucrose and polyol, with moisture content of approximately not more than 3%, in form of a first separate composition, and a container for this first separate composition; and b) introduction carrier, which contains a solvent for reducing (dissolving) the said composition and histidine in amount approximately ranging from 0.1 mM to 100 mM, and possibly a toxicity modifying agent in an amount sufficient for making isotonic the reduced solution, obtained from dissolving the first separate composition in the introduction carrier of the second separate composition, in form of the second separate composition, and a container for this second separate composition.EFFECT: invention provides for stability.21 cl, 9 ex, 6 tbl

Versions of gla domain of factor vii or viia // 2373282
FIELD: chemistry; biochemistry.SUBSTANCE: invention relates to biotechnology, specifically to production of versions of the Gla domain of human factor VII or human factor VIIa, and can be used in medicine. Amino acid sequence of the FVII or FVIIa version is obtained, which differs on 1 to 15 amino acid residues with amino acid sequence of the human factor VII (hFVII) or human factor VIIa (hFVIIa), in which a negatively charged amino acid residue is introduced by substitution in position 36. Obtained variants of FVII or FVIIa are used in a composition for treating mammals with diseases or disorders, where blood clotting is desirable.EFFECT: invention allows for producing versions of FVII or FVIIa with high clotting activity and/or high activation of factor X, compared to natural form of hFVIIa.42 cl, 3 dwg, 5 tbl, 11 ex

Eukaryotic host cell for expression vitamin k dependent protein, expression vector in eukaryotic cells, method for making gamma-carboxylated vitamin k dependent protein and method for making pharmaceutical composition for coagulation induction or stimulation of coagulation increase or decrease // 2372401
FIELD: medicine.SUBSTANCE: vitamin K dependent protein is made by separating a cultivated eukaryotic cell that contains an expressing vector that contains a nucleic acid molecule coding vitamin K dependent protein and associated sequences regulating expression. The associated sequences contain the first promoter and the nucleic acid molecule coding gamma-glutamylcarboxylase, and the second promoter. The first promoter represents a pre-early promoter of human cytomegalovirus (hCMV), and the second promoter is a pre-early promoter SV40. Herewith the expressing relation of vitamin K dependent protein and gamma-glutamylcarboxylase is 10:1 to 250:1.EFFECT: invention allows for making gamma-carboxylated vitamin K dependent protein in production quantities.29 cl, 5 dwg, 6 tbl, 7 ex
ethod of fibrin powder obtainment // 2371185
FIELD: medicine.SUBSTANCE: invention concerns medicine, particularly hematology and obtainment of medicines out of animal and human blood. Invention claims simple method of fibrin powder obtainment, involving fibrin separation from blood clot, flushing by distilled water, drying by filter paper till complete water evaporation, and further grinding and sterilisation of target product. After drying by filter paper separated fibrin is placed for 2-4 hours to 9-10% ammonium solution in amount of 1 g of raw fibrin per 4-6 ml of solution, and then it is dried at 30-45°C till complete evaporation of water and ammonium.EFFECT: simplified procedure, obtainment of sterile hygroscopic fibrin powder.

Stabilised solid compositions of vii factor polypeptides // 2366451
FIELD: medicine.SUBSTANCE: invention refers to chemically and physically stable compositions containing VII factor or polypeptide, related to VII factor, so such compositions can be stored, available and applicable at room temperature. The composition contains effective amount of VII factor polypeptide, and sucrose and polyol combination with humidity about 3% or less. The invention also concerns the method for preparing stable VII factor polypeptide as involving stages of introduction of said VII factor polypeptide in a solution containing sucrose and polyol combination as a stabiliser, and processing of said solution to produce a solid composition. In addition to sucrose and polyol combination, an antioxidant that is, e.g. homocysteine, cysteine, cystathionine, methionine or glutathione, can be added. Polyol represents, e.g. mannitol, sorbite or xylite. There is also disclosed method for treatment of reactive syndrome of VII factor that involves introduction of VII factor combined with sucrose and polyol. There is also offered application of VII factor polypeptide to prepare a medical product used for treatment of reactive syndrome of VII factor. The invention is related to stable compositions of VII factor polypeptide that does not contain degradation products and does not show decreasing activity of VII factor polypeptides if stored in natural conditions within at least 6 months.EFFECT: improved stability of the composition.48 cl, 12 ex, 7 tbl

Conjugate of factor vii polypeptide, method of obtaining it, its application and pharmaceutical composition containing it // 2362807
FIELD: biotechnologies.SUBSTANCE: invention relates to field of biotechnology, namely to obtaining factor VII polypeptides and can be used in medicine. Obtained is conjugate of factor VII polypeptide, including factor VII polypeptide with asparagine-bonded and/or serine-bonded oligosaccharide chains, which include sialic acid or galactose fragments. At least one of oligosaccharide chains is covalently bonded with at least one polymer group representing polyethyleneglycol, which has molecular weight within the range 300-100000 Da. Obtained conjugate of factor VII is used in pharmaceutical composition for treatment of factor VII reactive syndrome.EFFECT: invention allows to obtain conjugate of factor VII with PEG with set glycolysing character for obtaining homogeneously modified preparation.22 cl, 1 dwg, 4 ex

Preparation inhibiting malignant tumour development and containing dis-a-fibrin // 2358754
FIELD: medicine.SUBSTANCE: preparation inhibiting malignant tumour development contains dis-A-fibrin and may inhibit malignant tumours by inhibiting distribution and migration of malignant tumour cells thereby may inhibit malignant tumour development.EFFECT: inhibition of tumour invasion and dissemination.8 cl, 4 ex, 2 tbl, 9 dwg

Liquid composition of factor vii polypeptides // 2357751
FIELD: medicine.SUBSTANCE: invention concerns medicine, particularly liquid composition of factor VII polypeptides. Invention claims liquid aqueous composition including (i) factor VII polypeptide, (ii) substance suitable for pH maintenance approximately within 4.0 to 8.0, (iii) substance selected out of list including calcium salt, magnesium salt or their mix, where (iii) concentration comprises at least 15 mM, and antioxidation agent.EFFECT: enhanced stability.33 cl, 7 ex, 1 dwg
ethod for making human coagulation factor ix concentrate // 2353386
FIELD: medicine.SUBSTANCE: invention refers to biotechnology and pharmaceutical industry area and concerns methods for making frozen-dried high-purity blood plasma factor IX preparation. In the present invention supernatant made of plasma after solvent-detergent processing is applied on an anion-exchange column to concentrate factor IX and remove viral inactivation components. Then salt fractionation follows with ammonium sulphate. This reasonably priced and effective stage allows eliminating the majority of prothrombin-complex impurity factors with keeping those components well separated from end protein at the following stage. The last stage involves final purification by metalchelate chromatography. The problem of the invention is to simplify blood plasma factor IX technology enabling for high-active product to be effective in clinical practice.EFFECT: invention aims at simplifying the method for making coagulation factor IX of high specific activity of protein 150-200 ME/mg.2 cl, 2 ex

Antibodies bispecific to erb-b and their application in tumour treatment // 2349340
FIELD: medicine, pharmaceutics.SUBSTANCE: invention concerns medicine, particularly immunotherapy. Invention claims bispecific antibody and its application in tumour treatment. New antibody can link to EGF receptor and includes two antigene-binding sites linking to different epitopes of indicated receptor, thus ensuring higher receptor engagement by antibodies at the same dosage. It allows for higher antibody density on receptor and significant inhibition of tumour growth and/or enhancement of solid tumour or metastasis apoptosis.EFFECT: higher receptor engagement by antibodies at the same dosage.16 cl, 2 ex
 
2551257.
Up!